Contact this trialFirst, we need to learn more about you.
Anti-metabolites
Azacitidine + Pembrolizumab for Hodgkin's Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a new combination treatment for people with relapsed or refractory Hodgkin lymphoma. The treatment consists of azacitidine and pembrolizumab, and it will be given to patients at a single center. The trial will assess how well the treatment works, how safe it is, and how well patients tolerate it.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.